
    the study was prematurely terminated on 06 october 2016 due to the potential risk of further
    dosing in healthy subjects
  
['healthy']
['pf-06687234', 'placebo']

        INCLUSION CRITERIA

          -  Healthy females of non childbearing potential and healthy males

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

          -  Ability to personally sign and date the informed consent document and able to comply
             with schedule of activities

          -  For Single Dose Cohort 7 only, Japanese subjects must have four biological Japanese
             grandparents born in Japan.

        EXCLUSION CRITERIA

          -  Evidence or history of clinically significant health concerns

          -  Treatment with an investigational drug within 30 days

          -  Exposure to any live vaccines within 28 days prior to investigational product
             administration.

          -  History of drug and/ or alcohol abuse and tobacco use equivalent of 5 cigarettes per
             day.

          -  Known history of infection with hepatitis B virus, hepatitis C virus, or human
             immunodeficiency virus

          -  Pregnant female subjects

          -  History of sensitivity to heparin

          -  Unwilling or unable to comply with the Lifestyle Guidelines as stated in the protocol
      